Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID IN PLASTIC CONTAINER versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID IN PLASTIC CONTAINER versus RESPORAL.
CEFOBID IN PLASTIC CONTAINER vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
2 g IV every 8-12 hours; usual total daily dose 4-6 g, severe infections up to 12 g daily divided q8h.
2 mg orally twice daily
None Documented
None Documented
2.2 hours (normal renal function); prolonged to 4-5 hours in elderly or hepatic impairment; in severe renal failure (CrCl <10 mL/min), may extend up to 8 hours.
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Renal: 65-85% unchanged; biliary: 10-20% (fecal elimination); total renal clearance approximates glomerular filtration rate.
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic